NeuroOne Q3: Revenue Up 16%, But Cash Drops to $2.0M and Going Concern Doubt Persists
NMTC is trading near its 52-week low of $1.423 (2.6% above the low).
Summary
NeuroOne's Q3 revenue grew 16% to $2.0M with record gross margins, but cash fell to $2.0M and going concern doubt persists. The company needs additional capital by January 2027.
Key Events · Earnings and Guidance · NMTC
-
Q3 Revenue Up 16%, Gross Margin Record
Product revenue rose 16% to $1.97M for the quarter, with gross margin improving to 59.9% from 53.9% a year ago.
-
Cash Drops to $2.0M, Going Concern Doubt
Cash and equivalents fell to $2.05M from $6.57M at fiscal year-end. Management reiterates substantial doubt about going concern and estimates runway only into January 2027.
-
Material Weaknesses Unremediated
Two material weaknesses in internal controls remain unremediated: insufficient segregation of duties and ineffective revenue recognition controls that caused the Q1 restatement.
-
Subsequent ATM Issuance and Warrant Reset
On July 13, 2026, the company issued 400,346 shares for $1.04M under the ATM, triggering a PIPE warrant exercise price reset to $2.5227.
Analysis · NMTC · Industrial Applications And Services
NeuroOne's Q3 FY2026 revenue grew 16% to $2.0 million with record 59.9% gross margins, but cash fell to $2.0 million and the company reiterates substantial doubt about its ability to continue as a going concern. Management estimates current cash plus ATM proceeds fund operations only into January 2027. The company also discloses two unremediated material weaknesses in internal controls and a subsequent ATM issuance of 400,346 shares for $1.04 million that reset PIPE warrant exercise prices lower. The stock trades near its 52-week low, and the new Nasdaq MVLS Rule could trigger immediate delisting if market value falls below $5 million.
At the time of this filing, NMTC was trading at $1.46 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $13.2M. The 52-week trading range was $1.42 to $6.96. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.